# LAI Weekly Intelligence: December 12, 2025

This week's intelligence highlights significant advances in long-acting injectable technology, featuring strategic partnerships and clinical breakthroughs that underscore the sector's momentum. Key developments include Moderna's entry into extended-release formulations and continued progress in therapeutic applications.

## TL;DR

- Moderna partners with Nanexa to develop PharmaShell extended-release injectable technology
- UZEDY demonstrates positive Phase 3 results for extended-release aripiprazole formulation
- MedinCell secures €2.5M grant to advance BEPO-based malaria prevention LAI

---

## Technology & Innovation

Strategic partnerships and clinical validation drive innovation in extended-release injectable platforms.

**Nanexa and Moderna Announce PharmaShell Technology Partnership**  
Nanexa AB has entered into a strategic partnership with Moderna to develop PharmaShell technology for extended-release injectable formulations. This collaboration marks Moderna's expansion into long-acting delivery systems leveraging Nanexa's proprietary platform.  
[Read more](#)

**UZEDY (aripiprazole) Extended-Release Injectable Shows Positive Phase 3 Results**  
Teva Pharmaceutical has announced positive Phase 3 clinical trial results for UZEDY, a novel extended-release injectable formulation of aripiprazole. The results demonstrate the therapeutic potential of this next-generation LAI antipsychotic treatment.  
[Read more](#)

---

## Funding & Business Development

Investment activity reflects growing confidence in LAI therapeutic applications and platform technologies.

**Nanexa and Moderna Announce PharmaShell Technology Partnership**  
The strategic alliance between Nanexa AB and Moderna focuses on developing PharmaShell technology for extended-release injectable formulations. This partnership represents a significant business development milestone for both organizations in the LAI sector.  
[Read more](#)

**MedinCell Receives €2.5M Grant for Malaria Prevention LAI Development**  
MedinCell has secured a €2.5 million grant to advance development of a long-acting injectable malaria prevention treatment using its BEPO technology platform. This funding supports the expansion of LAI applications into critical global health challenges.  
[Read more](#)

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
